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ABSTRACT
Genetic modifications or mutations has been a bottleneck for the treatment of cancer; it is widely known to play a vital role in the progression of 
metastatic level/stage within the nonsmall cell lung cancer (NSCLC). The NSCLC of cancer is responsible for lung cancer lawsuits. In the various genetic 
mutations related study has been concluded with the various genes findings, which are named as the epidermal growth factor receptor, anaplastic 
lymphoma kinase, Kristen rat sarcoma virus, ROS proto-oncogene 1, human epidermal growth factor, B-RAF proto-oncogene, rearranged during 
Transfection, MET, Phosphatidyl 3-kinases CA, IGF-1R, NTRK1, FGFR1, and DDR2. The various research data supported this study. The involvement 
of the gene in the NSCLC patients made a paradigm shift in the drug discovery. The presence of one mutation in connection with some other could 
have an impact on NSCLC remedy.Utilizing this genotype-directed therapy for an advanced NSCLC has to turn out to be an appealing and efficacious 
treatment strategy. Here in the advancement of research, related genetic modulated targets and treatment have been discussed, particular genetic 
mutations help to find new updated interventions or medicinal drugs for the treatment of NSCLC. In there view, we have comprehensively arranged 
the mutation type and treatment with the status of NSCLC.
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INTRODUCTION
Introduction: Lung cancer
Lung cancer is the categorically found in lung tissues, mainly in the air 
passages of cells lining. Lung cancer conventionally categorized into 
two types as follows: (1) Small cell lung cancer (SCLC) and (2) non-
SCLC (NSCLC) [1]. Among the all lung cancers, approximately 85% 
are recognized as nonsmall cell, and approximately 75% of these are 
metastatic, or advanced, at diagnosis level [2,3]; however, SCLC, also 
known as oat cell cancer and approximately (10-15%) of all lung cancers. 
The major difference in between SCLC and NSCLC can be identified 
under easily by the simple microscopy technique. The SCLC cells appear 
small and originally packed with the nucleus (cell control center) [4]. 
NSCLC is further categorized in adenocarcinoma, large cell carcinoma 
and squamous cell carcinoma, which are grouped collectively due to the 
fact they behave in a similar manner and respond to remedy in a similar 
way [4-6]. Common signs and symptoms in NSCLC including chest pain, 
hoarseness, weight loss, cough, shortness of breath, bone ache, yellowing 
of skin and eyes, and lumps close to the surface of the body [4].
In the last year (2017) report about lung cancer gave the surprising 
result about the case of lung cancer, it revealed that the number of new 
cases 222,500 of lung cancer and 155,870 deaths from lung cancer 
predicted by the American Cancer Society in the United States [3,4]. 
Lung cancer is the leading cause of most cancers loss of life among all 
type of cancers. Among the all types of genetically define people affected 
from lung cancer is more than other type named as colon, breast, and 
prostate cancers [4,7]. Survival rate varies by gender and cancer stage at 
the time of diagnosis. From the report of the surveillance, epidemiology, 
and results program, the relative survival rate of 5 years is 15% for men 
and 21% for women and the 5-year survival rate of NSCLC patients 
in different stages, stage IA (49%), stage IB (45%), stage IIA (30%), 
stage IIB (31%), stage IIIA (14%), stage IIIB (5%), and metastatic or 
stage IV (1%) [4] at different tumor stages, the mechanism of NSCLC 
progression may be different [8] and specific. The genetic mutation 
helps to identify better target drug treatment for NSCLC patients [5,8]. 
In almost all the cases of malignancy, these genetic modifications are 
acquired during a person’s lifetime and are available in specific cells 
in the lung. These mutations, can be referred as somatic mutations, 
which are not inherited. Somatic mutations in lots of unique genes 
have been located in lung malignancy cells. Cancer occurs due to the 
genetic mutations in vital genes, specifically those that manipulate cell 
development and division or DNA damage repair. These modifications/
mutations enable cells to develop and divide widely to form a tumor [9].
Genetic modifications in NSCLC
Lung cancer is a major type among other many distinct subsets of cancer 
that can classify by way of numerous factors, including histology and the 
molecular make-up of a tumor [2,10]. Genetic changes in lung cancer 
disease caused by certain changes to genes that decide that how our cells 
grow and divide. The genetic changes include DNA mutations, which 
affect the genetic functions or molecular mechanisms known as molecular 
abnormalities. The molecular abnormalities are associated with growth-
promoting and genetic alterations or growth-promoting genes [11,12].
Genes, chromosomes, and DNA
Smoking is the major cause of lung cancer among the other risk factors. 
However, 25% of lung cancer patients are nonsmokers. Various reported 
a study of different molecular signature, etiology, histology, and location 
of NSCLC for smokers and nonsmokers [10]. Adenocarcinoma was 
found prevalent in nonsmoker NSCLC patients. There are certain genes 
and chromosomes that have a connection with an increased risk of 
lung cancer at the molecular level. Carriers of TP53 germline sequence 
variations which also prone for a smoker than three times more likely to 
develop lung cancer than nonsmokers. There are several reports for a 
marker on chromosome 15 associated with lung cancer. Our genes made 
up by DNA, which controls cells functions mostly the cell division process. 
However, DNA also can influence the risk for the development of certain 
diseases, such as different type of cancers. The DNA change appears in 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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the people who inherit a particular chromosome (chromosome 6) are 
more likely to develop lung cancer [5], but some genes such as oncogenes, 
which control cell growth, including division of new cells, are thought 
to be important in the development of NSCLC [4,13]. The identification 
and increased understanding of molecular abnormalities in lung 
cancer research is mainly involve in identifying of molecular targets 
including HER family of receptors, anaplastic lymphoma kinase (ALK), 
phosphatidylinositol 3-kinase (PI3K)/RAC-alpha serine/threonine-
protein kinase (AKT)/mTOR, epidermal growth factor receptor 
(EGFR), Kristen rat sarcoma virus (KRAS), IGF-1R, MET, and ROS [2,12]. 
The frequency of genetic alterations in NSCLC such as the oncogene 
KRAS mutated in approximately 30% of lung cancer cases; FGFR-1 
amplification (20%); ALK rearrangement (3–7%); AKT1 mutation (1%); 
DDR2 mutation (approximately 4%); human epidermal growth factor 
(HER2) mutation (2–4%); KRAS mutation (12–25%); MEK1 mutation 
(1%); NRAS mutation (1%); Phosphatidyl 3-kinases (PIK3) CA mutation 
(1–3%); PTEN mutation (4–8%); ROS proto-oncogene 1 (ROS1) 
rearrangement (1%); MYC (2.5–10%); Cyclin D1 (5%); EGFR mutation 
(10–35%); rearranged during transfection (RET) rearrangement 
(1%); and C-erbB2 (Her-2/neu) or BCL2 overexpression involved in 
approximately 25% of cases; MET amplification and B-RAF proto-
oncogene (BRAF) mutations present in about 1-3% of NSCLC [11,14]. 
This information was utilized to develop targeted therapies [2,10] for 
the treatment of NSCLC. Molecular mechanism of oncogenes including 
EGFR, AKT1, BRAF, HER2, KRAS, MEK1, MET, NRAS, PIK3CA, RET, and 
ROS1 are currently available targets, and the updation of drugs and the 
clinical trials status has been discussed.
EGFR
EGFR belongs to receptor tyrosine kinases (RTKs) [10,15] family that 
includes EGFR/ERBB1, HER2/ERBB2/NEU, HER3/ERBB3, and HER4/
ERBB4. The binding of growth factors or ligands, such as EGF, trigger 
a conformational change that facilitates homodimer or heterodimer 
receptor formation, thus resulting in activation of EGFR tyrosine kinase 
activity. Activated EGFR phosphorylates and its substrates, resulted in 
multiple downstream pathways activation within the cell The activation 
process involve the cell proliferation process by PI3K-AKT-mTOR, RAS-
RAF-MEK-ERKor MAPK and the PI3K-AKT-mTOR pathways, which 
involved in cell proliferation (Fig. 1) [16,17].
EGFR role in lung cancer
EGFR deregulation (62%) observed in NSCLC (~50% of non-smokers and 
5-15% smokers). EGFR mutations is most commonly found in various 
cancers subtypes including NSCLC in which it occur within its 4 exons 
(18–21), which encodes a portion of the Tyrosine kinase domain (Fig 2). 
Heterozygous mutations most prominent in EGFR, with the mutant allele, 
showing gene amplification and these point mutations occurred as exon 
19 deletions or exon 21 L858R point mutations accountable for 44% and 
41% EGFR-TK mutations, respectively. These mutations increase EGFR 
activity, leading to hyperactivity of downstream signalling pathways [18].
EGFR inhibitors used in NSCLC with EGFR gene mutations
Since EGFR dysregulation most common in NSCLC, small molecule 
Tyrosine Kinase Inhibitors,Erlotinib (Tarceva®, Roche); Gefitinib 
(Iressa®, AstraZeneca) and monoclonal antibodies (mAb) - Cetuximab 
(Erbitux®, Merck) [19] target the EGFR-TK activity and used in the 
treatment of EGFR mutation [17]. Erlotinib (Tarceva); afatinib (Gilotrif); 
gefitinib (Iressa), D761 and T854A can be used as a first-line treatment 
for advanced NSCLCs with EGFR gene mutations [17]. Osimertininb 
(Tagrisso) targets T790 mutation (methionine substitution for 
threonine) in axon 20 of EGFR gene which hinder the interaction 
of inhibitor with receptor [5,20]. Cetuximab and necitumumab 
(Portrazza), monoclonal antibodies that also target EGFR.
Treatments available for EGFR mutations
First generations EGFR tyrosine kinase inhibitors
The mechanism of action for EGFR-TKIs (first-generation): Blockage 
of the downstream signaling activation induced by EGFR through ATP-
binding sites binding [15,21,22].
Erlotinib (Tarceva®, Roche); Gefitinib (Iressa®, AstraZeneca); Cetuximab 
(Erbitux®, Merck) [19,23].
Erlotinib (Tarceva®, Roche): Erlotinib is reversibly EGFR-TKI and 
approved by Federal agency FDA as a first-line treatment for EGFR 
mutation in NSCLC patients mutation in 2013 [15,21].
Gefitinib (Iressa®, AstraZeneca): Gefitinib is taken into account as 
an oral first-generation EGFR TKI and approval by FDAas a first-line 
treatment for NSCLC patients with EGFR mutations in 2015 [15,21,24].
Cetuximab (Erbitux®, Merck): Cetuximab is a chimeric monoclonal 
antibody that is directly acts on the EGFR mutation in NSCLC [15,20,25,26].
Icotinib: Icotinib a Chinese drug and approved as selective EGFR-TKI in 
NSCLC [15].
Second generation EGFR TK inhibitors
The mechanism of action for EGFR TKIs (second-generation) is for the 
alteration of the non-heritable resistance that comes from the failure of first-
generation EGFR TKIs. Therefore, the operating mechanisms of second-
generation EGFR TKIs do not seem to be precisely like first-generation 
EGFR TKIs [15], for example, Afatinib (Giotrif®, BoehringerIngelheim); 
Dacomitinib (PF-0299804, Pfizer); Neratinib (HKI-272, Pfizer); Pelitinib 
(EKB-569, Wyeth/Pfizer); Canertinib (CI-1033, Pfizer) [19].
Afatinib (Giotrif®, BoehringerIngelheim): Afatinib is an aniline-
quinazoline derivative with a reactive acrylamide group which can 
modify the catalytic domains of EGFR, HER2, and ErbB-4, with orally 
bioavailable irreversible EGFR inhibitor and afatinibaction may longer 
than reversible EGFR TKIs [15,27].
Dacomitinib (PF-0299804, Pfizer): Dacomitinib is EGFR-TKI in NSCLC 
by targeting ErbB2 and ErbB4 kinase [15].
Neratinib (HKI-272, Pfizer):Neratinib is an irreversible pan-ErbB 
inhibitors and found with positive response in NSCLC patients with 
G719X mutations in EGFR [28].
Pelitinib (EKB-569, Wyeth/Pfizer):Pelitinib is a potent irreversible 
EGFR-TKI and currently in clinical trials for the NSCLC treatment [28].
Canertinib (CI-1033, Pfizer):Canertinib is 3-chloro,4-fluoro,4-
anilinoquinazoline and an irreversible inhibitor for TKI domain of the 
erbB receptors [29].
Fig. 1: Schematic diagram of EGFR signaling pathway [16]. Growth 
factor binding to EGFR results in activation of the MAPK signaling 
pathway (RAS-RAF-MEK-ERK) and the phosphatidylinositol 
3-kinase (PI3K) pathway (PI3K-AKT-mTOR). The letter “K” within 
the schema denotes the tyrosine kinase domain
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Third generations EGFR TK inhibitors
Nowadays, many EGFR TKIs used in the treatment of NSCLC patients. 
Unfortunately, all patients treated with gefitinib, erlotinib, or afatinib 
produces resistance. To an outsized extent, either non-inheritable 
or intrinsic resistance reduced the effectualness of EGFR TKIs. These 
reported mechanisms embody the event of T790M mutation, CMET 
amplification, HER2 amplification, microscopic anatomy transformation 
to small-cell microscopic anatomy. Among them, the foremost vital 
mechanism of non-inheritable resistance is the EGFR T790M mutation. 
It had been according that prevalence frequency of T790M mutation was 
from 49% to 63% when rebiopsies. To beat this new issue,completely 
difference third-generation EGFR-mutant-selective TKIs, similar to 
osimertinib, rociletinib, and olmutinib, appeared. These agents square 
measure specifically designed to inhibit EGFR T790M while not wild-
type EGFR, that structurally completely different from first-generation 
and second-generation inhibitors [15,30-32].
Osimertinib (taggriso, AZD9291): Osimertinibis an irreversible and 
selective inhibitor for both T790M mutation-positive EGFR and 
sensitizing EGFR mutation in NSCLC [15].
CO1686 (rociletinib): CO1686 is also third-generation irreversible 
EGFR-TKI in NSCLC [15].
AC0010: AC0010 is an irreversible inhibitor of EGFR mutants in NSCLC 
and based on pyrrolopyrimidine [15].
HM61713 (olmutinib):HM61713 is a selective inhibitor for T790M 
EGFR mutants except EGFR wild-type in NSCLC [15].
Fourth-generation EGFR TKI’s
In 32% of patients, the new EGFR C797S mutation occurring. Hence, 
the fourth-generation EGFR-TKIs appeared to overcome this mutation 
[15,31,33]. for example, EAI045.
EAI045: EAI045 only works in the combination with cetuximab and 
targets T790M and C797S EGFR mutations [15].
Clinical trials on EGFR in NSCLC
In the USA, 93 clinical trials including Phase-I (NCT02639091; 
NCT02637531; NCT02608385; NCT02595866; NCT02520778; 
NCT02563548; NCT02496663; NCT02475213; NCT02409108; 
NCT02381314; NCT02365662; NCT02364609; NCT02327468; 
NCT02309892NCT02309177; NCT02157792; NCT02143466; 
NCT02113813; NCT00889954; NCT02298153; NCT02071862; 
NCT02013219; NCT01999985), Phase II (NCT02132598; 
NCT02323126; NCT02314364; NCT02312622; NCT02045446; 
NCT01857271; NCT01854034; NCT01829217; NCT01702844; 
NCT01746251; NCT01620190; NCT01573702; NCT01553942; 
NCT01248247); Phase II and III (NCT02438722); Phase III 
(NCT02409342; NCT02193282); and no phase specified phases 
(NCT01294280; NCT02299141; NCT02194738; NCT02450591) and 
33 clinical trials going on in Phase I (NCT02358473; NCT01998126; 
NCT01967095; NCT01966445; NCT02088112; NCT01839955; 
NCT02206763; NCT02192541; NCT02191891); Phase I and 
II (NCT02155465; NCT02580708); Phase II (NCT02485652; 
NCT02454842; NCT02448303; NCT02318368; NCT01532089; 
NCT01336634; NCT01935947; NCT01928160; NCT01877083; 
NCT02119650; NCT02289833; NCT02271906; NCT01306045); 
Phase III (NCT02453282; NCT02352948; NCT02322281; 
NCT02296125; NCT02066636; NCT02134015); Phase IV 
(NCT02151149); no specified phase (NCT01416688; NCT00900328) 
at unknown locations for EGFR in NSCLC as a target is mentioned in 
Tables 1 and 2 [16].
Fig. 2: Schematic representation of EGFR genetic mutations [10,16]. Exons 18–21 of the EGFR kinase domain are depicted. Mutations 
above the schematic are associated with sensitivity to EGFR TKIs. Mutations listed below the schematic are associated with EGFR TKI 
resistance.
43
Asian J Pharm Clin Res, Vol 11, Issue 8, 2018, 40-55
 Kumar et al.
Table 1: Clinical trials on EGFR in NSCLC in the USA as mentioned below [16]
Phase Drug candidate Protocol id Current status 
Phase I BAY 94-9343, pemetrexed and cisplatin NCT02639091 Recruiting
IP1-549 and nivolumab NCT02637531 Recruiting
Stereotactic body radiation therapy+pembrolizumab NCT02608385 Recruiting
Pembrolizumab NCT02595866 Recruiting
Osimertinib and navitoclax NCT02520778 Recruiting
Pembrolizumab with PEDPH-20 NCT02563548 Recruiting
Necitumumab with EGFR inhibitor AZD9291 NCT02496663 Recruiting
Pembrolizumab+enoblituzumab (MGA271) NCT02475213 Recruiting
Exotherm total-body hyperthermia NCT02409108 Recruiting
Enoblituzumab (MGA271)+ipilimumab NCT02381314 Recruiting
ABBV-221 NCT02365662 Active, not recruiting
Pembrolizumab and afatinib dimaleate NCT02364609 Recruiting
INO-1400 vaccine+INO-9012 NCT02327468 Recruiting
l-DOS47 NCT02309892 Recruiting
Nab-paclitaxel/carboplatin NCT02309177 Active, not recruiting
VX-970 NCT02157792 Active, not recruiting
AZD9291+ascending doses of novel therapeutics NCT02143466 Recruiting
ASP8273 NCT02113813 Active, not recruiting
Autologous cytotoxic t-lymphocytes NCT00889954 Active, not recruiting
Atezolizumab (MPDL280A)+epacadostat (INCB024360) NCT02298153 Terminated
Glutaminase inhibitor cb-839 NCT02071862 Recruiting
Atezolizumab+erlotinib or alectinib NCT02013219 Active, not recruiting
Afatinib dimaleate and dasatinib NCT01999985 Active, not recruiting
Phase II Cabozantinib-s-malate NCT02132598 Recruiting
Nivolumab+EGF816 and nivolumab+INC280 NCT02323126 Recruiting
Stereotactic body radiation therapy NCT02314364 Recruiting
Pegylated irinotecan NKTR-102 NCT02312622 Recruiting
Maintenance chemotherapy with or without stereotactic 
body radiation therapy 
NCT02045446 Active, not recruiting
Erlotinib hydrochloride before surgery NCT01857271 Recruiting
HSP90 inhibitor AUY922 NCT01854034 Completed
Sunitinib malate NCT01829217 Active, not recruiting
Paclitaxel albumin-stabilized formulation NCT01702844 Active, not recruiting
Afatinib dimaleate NCT01746251 Active, not recruiting
Paclitaxel albumin-stabilized nanoparticle formulation NCT01620190 Active, not recruiting
Stereotactic radiosurgery and Erlotinib hydrochloride NCT01573702 Active, not recruiting
Afatinib dimaleate, combination chemotherapy, and 
radiation therapy
NCT01553942 Recruiting
Erlotinib hydrochloride, AKT inhibitor MK2206, 
selumetinib, or sorafenib tosylate 
NCT01248247 Active, not recruiting
Phase II, Phase III Afatinib dimaleate with or without cetuximab NCT02438722 Recruiting
Phase III Aatezolizumab (MPDL3280A) compared with cisplatin or 
carboplatin+pemetrexed or gemcitabine 
NCT02409342 Recruiting
Erlotinib hydrochloride NCT02193282 Recruiting
No phase specified Adjuvant chemotherapy NCT01294280 Recruiting
Nintedanib NCT02299141 Recruiting
Surgery NCT02194738 Recruiting
Local therapy and erlotinib hydrochloride NCT02450591 Completed
NSCLC: Non-small cell lung cancer, AKT1: RAC alpha serine/threonine-protein kinase, HSP90: Heat shock protein-90
Phase Drug candidate Protocol id Current status
Phase I Mogamulizumab+docetaxel NCT02358473 Completed
Immune checkpoint inhibitor and erlotinib 
hydrochloride or crizotinib
NCT01998126 Active, not recruiting
Low- and high-dose erlotinib hydrochloride NCT01967095 Active, not recruiting
GSK2849330 NCT01966445 Completed
MEDI4736 (anti pd-l1)+gefitinib NCT02088112 Active, not recruiting
Erlotinib hydrochloride and quinacrine dihydrochloride NCT01839955 Completed
Erlotinib and momelotinib NCT02206763 Terminated 
Ganetespib and ZIV-aflibercept NCT02192541 Terminated
BI 836845 plus afatinib NCT02191891 Active, not recruiting
Phase I, 
Phase II
Ruxolitinib phosphate and erlotinib hydrochloride NCT02155465 Completed
Rociletinib+trametinib NCT02580708 Completed
Phase II HM61713 NCT02485652 Active, not recruiting
Pembrolizumab and acalabrutinib NCT02448303 Active, not recruiting
Ficlatuzumab plus erlotinib versus placebo plus erlotinib NCT02318368 Terminated
Erlotinib hydrochloride with or without bevacizumab NCT01532089 Active, not recruiting
Dabrafenib monotherapy+dabrafenib and trametinib NCT01336634 Active, not recruiting
Table 2: Clinical trials going on at unknown locations for EGFR in NSCLC as mentioned below [16]
(Contd...)
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AKT1
AKT1 oncogenic mutations are non-overlapping with other mutations 
which found in NSCLC. AKT1 is related to the serine-threonine protein 
kinases family which also includes subtypes AKT2 and AKT3. AKT1 
plays a key role in cell growth, angiogenesis, proliferation, and survival. 
The distinct roles of the AKT isoforms in NSCLC are largely unknown, 
but AKT1 also downregulates PI3K pathway (Fig. 1) [33-37].
Treatments available for AKT1 mutations
•	 Ipatasertib	(GDC	0068),	which	targets	all	three	isoforms	of	AKT	[38,39].
•	 Uprosertib	(GSK	2141795),	also	another	inhibitor	of	all	AKT	isoforms,	
and in combination with oral MEK1/2 inhibitor, it is showed better 
results in the trials, still it is unclear the role of drug for lung cancer 
patients [38].
•	 MK2206,	 an	 another	 allosteric	AKT	 inhibitor,	which	potentiate	
erlotinib activity in NSCLC cell lines as well as resensitized cells 
which developed erlotinib resistance through the HGF–MET axis. In a 
Phase II trial, MK220 with erlotinib for patients with advanced NSCLC 
progressed after previous response to erlotinib (NCT01294306), 
In	Phase-I	trial,	MK2206	and	gefitinib	in	NSCLC	patients	also	active	
(NCT01147211) [38]. MK-2206 in combination with erlotinib in 
NSCLC cell lines showed synergistic growth inhibition [40].
•	 Perifosine,	is	a	phospholipid	derivative	of	alkyl	phosphocholine;	in	Phase	
I/II trials an oral AKT inhibitor studied for NSCLC (NCT00399789). 
Perifosine and radiation also recommended in NSCLC [40].
•	 RX-0201	 (Archexin), 	 is 	 a 	 nano-polymer	 Akt	 antisense	
oligonucleotideanticancer drug [40].
•	 Erucylphosphocholine,	is	structurally	related	to	perifosine	appears	
to inhibit Akt [40].
•	 PBI-05204,	a	derivative	of	Nerium oleander and an inhibitor of Akt [40].
•	 GSK690693,	appeared	 to	delay	 tumor	growth	 irrespective	of	Akt	
activation status [40].
•	 XL-184,	a	dual	inhibitor	of	Akt	and	p70S6K	[40].
Clinical trials on AKT1
In the USA, two clinical trials including Phase II (NCT02642042; 
NCT01248247) and some clinical trials at unknown locations in Phase 
II (NCT02271906; NCT01306045) are going on AKT1 as a target 
mentioned in Tables 3 and 4 [35].
BRAF
BRAF belongs to a family of serine-threonine protein kinases that 
includes A-Raf Proto-Oncogene and C-Raf Proto-Oncogene. RAF kinases 
are significant mediators in the MAP kinase signaling cascade and exert 
their impact predominantly via phosphorylation and MEK activation. 
This occurs following the (hetero or homo) dimerization of the RAF 
molecules. As a part of the MAP kinase pathway, RAF is involved in 
many cellular approaches, along with differentiation, cell proliferation, 
and transcriptional regulation. BRAF mutation implicated in the 
pathogenesis of several cancers, including melanoma, NSCLC, colorectal 
cancer, papillary thyroid cancer, and ovarian cancer.BRAF mutations 
also observed in glioma and gastrointestinal stromal tumor (GIST) [41]. 
RAF receptor contains the regulative domain, associate in nursing 
activation loop, and a carboxyl terminus that contains the enzyme 
domain. The regulative domain is found among exons 1–10 within the 
amino (N) terminus, whereas the enzyme domain is found among exons 
11–18 at the carboxyl (C) terminus (Fig. 3) [17,42-46].
Treatment available for BRAF inhibition
•	 Vemurafenib,	 a	 selective	BRAFV600 inhibitor in the treatment of 
progressive BRAF mutant NSCLC [42,47].
•	 Dabrafenib,	is	an	another	a	selective	BRAFV600 inhibitorin NSCLC and 
could represent a treatment option for a population of patients with 
limited therapeutic options [42,48].
Clinical trials on BRAF
In the USA, nine clinical trials in Phase I NCT02595866; Phase II 
(NCT01827384); Phase I, Phase II (NCT02452424; NCT02437136; 
Phase Drug candidate Protocol id Current status
Azacitidine and entinostat NCT01935947 Terminated
Pemetrexed disodium and carboplatin or 
cisplatin±erlotinib hydrochloride or gefitinib
NCT01928160 Withdrawn
Lenvatinib (E7080) NCT01877083 Active, not recruiting
Ruxolitinib+pemetrexed/cisplatin NCT02119650 Terminated
Trastuzumab emtansine NCT02289833 Active, not recruiting
Afatinib dimaleate BIBW 2992 NCT02271906 Terminated
AZD6244, MK-2206, lapatinib NCT01306045 Recruiting
Phase III MEDI-4736±tremelimumab, paclitaxel+carboplatin NCT02453282 Active, not recruiting
MEDI-4736+tremelimumab and 
vinorelbine+gemcitabine
NCT02352948 Active, not recruiting
Rociletinib (CO-1686), rociletinib, pemetrexed or 
gemcitabine or paclitaxel or docetaxel
NCT02322281 Active, not recruiting
AZD9291 versus gefitinib or erlotinib NCT02296125 Active, not recruiting
Nivolumab NCT02066636 Active, not recruiting
Patritumab, erlotinib, placebo NCT02134015 Terminated
Phase IV Abraxane+carboplatin NCT02151149 Completed
No phase 
specified
Cetuximab, panitumumab, or erlotinib hydrochloride NCT01416688 Active, not recruiting
Laboratory biomarker analysis NCT00900328 Completed
EGFR: Epidermal growth factor receptor, NSCLC: Non-small cell lung cancer
Table 2: (Continued)
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NCT02428712; NCT02404441; NCT02327078; NCT02178722; 
NCT01325441) and some clinical trials at unknown locations in Phase 
I, Phase II (NCT01449058); Phase II (NCT01336634; NCT01306045) 
are going on BRAF as a target mentioned in Tables 5 and 6 [41].
ALK
It is responsible for 3–7% of all lung cancers [5,49]. For instance, 
activating missense mutations within full-length ALK are found in a 
subset of neuroblastomas [49]. The rearrangement in EML-4-ALK is the 
most common ALK rearrangement seen in NSCLC patients [5]. In non-
smoker lung cancer patients, EML-4 mutations are common or had been 
light smokers whose tumors lack both EGFR and KRAS mutations [5]. 
Using comparison, ALK fusions found in anaplastic large cell lymphoma 
(e.g., NPM-ALK, colorectal cancer, inflammatory myofibroblastic 
tumor). ALK fusions include the whole ALK tyrosine kinase domain. 
Finally, the ALK copy number and protein expression aberrations have 
also been found in rhabdomyosarcoma [49]. Other ALK mutations do 
not been found involving EML-4, including KIF5B-ALK and TFG ALK. 
Regarding treatment, patients suffered from EML4-ALK fusions or 
ALK rearrangements not benefited from EGFR-specific tyrosine kinase 
inhibitor therapy in NSCLC and ovarian cancer [49-52].
The N-terminal fusion partners (X) promote dimerization and growth 
factor binding potentiate ALK tyrosine kinase activity results in the 
cell growth, proliferation, and anti-apoptosis. Signaling downstream of 
ALK fusions results in the activation of cellular pathways known to be 
involved in cell growth and cell proliferation (Fig. 4) [49].
Interventions for the treatment of ALK mutations
ALK fusion oncogene associated with advanced NSCLC is highly 
sensitive to ALK tyrosine kinase (TK) inhibitors [51,53].
•	 Crizotinib,	(Xalkori®,	Pfizer),	is	indicated	as	second-line	therapy	and	
targets activated RTKs that result from EML4-ALK and other ALK 
fusions. Previously untreated advanced non-squamous ALK-positive 
NSCLCsufferers had been randomized to receive crizotinib 250 mg by 
mouth twice a day (n=172). Intravenous chemotherapy(pemetrexed 
500 mg plus either cisplatin 75 mg or carboplatin all administered 
intravenously	every	three	weeks	for	≤6	cycles,	n=171)	[5].
•	 Ceritinib,	is	a	second-generation	ALK	inhibitor	and	approximately	
20 times more potent than Crizotinib [53]. FDA approved, ceritinib 
for patients who have been intolerant of crizotinib. In clinical and 
preclinical studies, ceritinib showed activity against cells that were 
either sensitive or resistant to crizotinib and including with the most 
common L1196M and G1269A resistance mutations [53].
•	 Alectinib,	is	another	second-generation	ALK	inhibitor	that	showed	
activity in crizotinib-resistant lung cancer along with brain cancer. 
It approved by FDA for the treatment of patients with an ALK-
positive mutation in NSCLC patients who have shown intolerance 
for crizotinib [53].
•	 Brigatinib,	is	an	under	investigation	for	ALK	inhibition	that	yet	not	
approved for clinical use. However, brigatinib associated with early 
pulmonary toxicity in a small percentage of cases [53].
•	 Lorlatinib,	is	another	investigational	ALK	inhibitor	that	has	shown	
promising activity in a phase I study. Importantly, lorlatinib has 
proven past time in patients whose tumors harbor the highly 
resistant mutation ALK G1202R. This mutation confers resistance 
to different next-generation ALK inhibitors, including ceritinib, 
alectinib, and brigatinib [53].
Table 3: Clinical trial on AKT1 in NSCLC as mentioned below [48]
Phase Drug Candidate Protocol id Current status
Phase II Docetaxel, laboratory biomarker analysis, 
trametinib
NCT02642042 Recruiting
Erlotinib hydrochloride, MK2206, selumetinib, 
or sorafenib tosylate 
NCT01248247 Active, not recruiting
NSCLC: Non-small cell lung cancer, AKT1: RAC alpha serine/threonine-protein kinase
Table 4: Clinical trial on AKT1 in unknown locations in NSCLC as mentioned below [48]
Phase Drug candidate Protocol id Current 
status
Phase II Afatinib dimaleate before surgery BIBW 2992 NCT02271906 Terminated
Targeted enzyme inhibitor therapy (AZD6244, MK-2206, 
lapatinib)
NCT01306045 Recruiting
NSCLC: Non-small cell lung cancer, AKT1: RAC alpha serine/threonine-protein kinase
Fig. 3: BRAF mutations within the kinase domain (Red bar): In 
exons 11 and 15. The activation segment and conserved glycine 
motif (G-loop) (Grey bar): In exon 11 and in exon 15.
Fig. 4: Cell signaling pathway of ALK. Dimerization of the 
ALK fusion mediated by the fusion partner (“X”), results in 
constitutive activation of the ALK tyrosine kinase. ALK signaling 
results in pro-growth and anti-apoptosis.
46
Asian J Pharm Clin Res, Vol 11, Issue 8, 2018, 40-55
 Kumar et al.
Clinical trials on ALK1
In the USA, 62 clinical trials including in Phase I (NCT02639091; 
NCT02637531; NCT02608385; NCT02595866; NCT02563548; 
NCT02422589; NCT02451930; NCT02511184; NCT02409108; 
NCT02393625; NCT02309892; NCT02321501; NCT02013219; 
NCT01730118; NCT01803282; NCT01772004; NCT02299505);Phase 
II (NCT02420314; NCT02414139; NCT02568267; NCT02513667; 
NCT02498613; NCT02591615; NCT02314364; NCT02312622; 
NCT02132598; NCT02045446; NCT01935336; NCT01928576; 
NCT01829217; NCT01822496; NCT01752400; NCT01228435; 
NCT01702844; NCT02336451; Phase I, II (NCT01970865; NCT01325441; 
NCT02584634; NCT02554812; NCT02523469; NCT02521051; 
NCT02487095; NCT02437136; NCT02408016; NCT02404441; 
NCT02403193; NCT02335918; NCT02327078; NCT02292550); Phase 
II & III (NCT02154490); Phase III (NCT02504489; NCT02595944; 
NCT02657434; NCT02201992; NCT02409342; NCT02193282); no 
specified phase (NCT02178163; NCT02194738; NCT02299141) 
and some clinical trials in Phase I (NCT02358473; NCT02192541; 
NCT01998126; NCT01839955); Phase II (NCT01336634; NCT01306045; 
NCT01935947; NCT01877083); Phase III (NCT01828112); no specified 
Phase (NCT00900328) at unknown locations are going on ALK1 as a 
target mentioned in Tables 7 and 8 [49].
ROS1
ROS1 is related to a RTK of the insulin receptor family [54] that 
acts as a driver oncogene in 1–2 % of NSCLC through a genetic 
translocation between ROS1 and other genes, the most common of 
which is CD74 [54] chromosomal rearrangements regarding the ROS1 
gene, on chromosome 6q22, were initially described in glioblastomas 
(e.g., ROS1). More recently, ROS1 fusions identified as a potential 
”driver“ oncogene in NSCLC and cholangiocarcinoma [54]. ROS1 
fusions incorporate a tyrosine kinase domain. Till date, those tested 
biologically possess oncogenic activity. Signaling downstream of ROS1 
fusions outcomes in the activation of cellular pathways recognized too 
concerned with cell proliferation and cell growth (Fig. 1). ROS1 fusions 
are related to sensitivity in-vitro to tyrosine kinase inhibitors that 
inhibit ROS1 [54,55].
Interventions for ROS1 inhibition
•	 Crizotinib	(xalkori):	Is	highly	active	and	used	as	first	line	treatment	
or greater in patients with the advanced ROS1 arrangement of NSCLC 
[56,57].	Xalkori	 is	 the	 first	and	only	FDA-approved	 treatment	 for	
patients with ROS-1 positive NSCLC [57,58].
Clinical trials on ROS1
In the USA, eight clinical trials Phase I (NCT02637531; NCT02595866); 
Phase II (NCT02568267; NCT02426658; NCT02314364; NCT01702844; 
NCT01639508); Phase I, II (NCT01970865) and some clinical trials in 
Phase I (NCT01839955) at unknown locations are going on ROS1 as a 
target mentioned in Tables 9 and 10 [54].
HER2
It belongs to a RTKs family that includes EGFR/ERBB1, HER2/ERBB2/
NEU, HER4/ERBB4, and HER3/ERBB3. The gene for HER2 is placed 
on chromosome 17 and found to amplify with an increased copy 
number of several cancers. Amplification of HER2 has been discovered 
to promote tumorigenesis and to be involved in the pathogenesis 
of several human cancers. Until now, no ligand recognized for HER2. 
However, HER2 appears to be the preferred dimerization associate for 
all members of the ERBB family. The binding of ligand followed by HER2 
heterodimerization outcomes in HER2 tyrosine kinase activation for 
activity. Then, activated HER2 phosphorylates its substrates, which lead 
to multiple downstream pathway activation, include PI3K-AKT-mTOR 
pathway and the RAS-RAF-MEK-ERK pathway, for involvement in cell 
proliferation, and cell survival, respectively (Fig. 5) [59].
Table 5: In USA, clinical trial on BRAF in NSCLC as mentioned below [40]
Phase Drug candidate Protocol id Current status
Phase I Pembrolizumab and laboratory biomarker analysis NCT02595866 Recruiting
Phase II Molecular profiling-based targeted therapy (adavosertib, 
carboplatin, everolimus)
NCT01827384 Suspended
Phase I, Phase II PLX3397+pembrolizumab NCT02452424 Active, not 
recruiting
Entinostat with pembrolizumab NCT02437136 Recruiting
PLX8394 NCT02428712 Recruiting
PDR001 NCT02404441 Recruiting
Nivolumab, epacadostat, chemotherapy NCT02327078 Recruiting
Pembrolizumab (MK-3475)+epacadostat (INCB024360) NCT02178722 Recruiting
BBI608, paclitaxel NCT01325441 Recruiting
NSCLC: Non-small cell lung cancer
Table 6: Some clinical trials on BRAF at unknown locations as mentioned below [40]
Phase Drug candidate Protocol id Current status
Phase I, Phase II MEK162+BYL719 NCT01449058 Completed 
Phase II Dabrafenib monotherapy+trametinib NCT01336634 Active, not recruiting
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Table 7: In USA, an around 62 clinical trials targeted as ALK in different phases mentioned below [48]
Phase Drug candidate Protocol id Current status
Phase I Anetumab ravtansine+pemetrexed and cisplatin NCT02639091 Completed
IPI-549 and nivolumab NCT02637531 Recruiting
Pembrolizumab and stereotactic body radiation therapy NCT02608385 Recruiting
Pembrolizumab and laboratory biomarker analysis NCT02595866 Recruiting
PEGPEM NCT02563548 Recruiting 
Ceritinib+warfarin and midazolam NCT02422589 Active, not recruiting
Necitumumab (LY3012211) and pembrolizumab (MK3475) NCT02451930 Active, not recruiting
Crizotinib plus pembrolizumab NCT02511184 Recruiting
Exatherm total-body hyperthermia NCT02409108 Recruiting
Ceritinib+nivolumab NCT02393625 Recruiting
L-DOS47 NCT02309892 Recruiting
Ceritinib (LDK378), ceritinib (LDK378) 750 mg, 
everolimus
NCT02321501 Recruiting
Atezolizumab+erlotinib or alectinib NCT02013219 Active, not recruiting
Autologous Ad HER2 dendritic cell vaccine NCT01730118 Recruiting 
Andecaliximab, gemcitabine, nab-paclitaxel NCT01803282 Active, not recruiting
Avelumab NCT01772004 Active, not recruiting
Ceritinib NCT02299505 Recruiting
Phase II Paclitaxel, carboplatin, ascorbic acid NCT02420314 Recruiting
INC280 (capmatinib) NCT02414139 Recruiting 
Entrectinib (RXDX-101) NCT02568267 Recruiting
Ceritinib and stereotactic ablative radiation therapy NCT02513667 Recruiting
Cediranib+olaparib and 18F-fluoromisonidazole, cediranib maleate, 
laboratory biomarker analysis
NCT02498613 Recruiting 
MK-3475, carboplatin, paclitaxel, pemetrexed NCT02591615 Recruiting
Stereotactic body radiation therapy NCT02314364 Recruiting
Pegylated irinotecan NKTR 102 and laboratory biomarker analysis NCT02312622 Recruiting
Cabozantinib-s-malate NCT02132598 Recruiting
Maintenance chemotherapy±stereotactic body radiation therapy NCT02045446 Active, not recruiting
Ponatinib hydrochloride NCT01935336 Recruiting
Azacitidine, entinostat, and nivolumab or nivolumab NCT01928576 Recruiting 
Sunitinib malate NCT01829217 Active, not recruiting
Erlotinib hydrochloride or crizotinib and chemoradiation therapy NCT01822496 Active, not recruiting 
AUY922 NCT01752400 Active, not recruiting 
IPI-504 NCT01228435  Terminated




PF-06463922 and crizotinib NCT01970865 Active, not recruiting
BBI608 and paclitaxel NCT01325441 Recruiting
Avelumab+crizotinib or PF-06463922 NCT02584634 Recruiting
Avelumab+other cancer immunotherapies NCT02554812 Recruiting
Nivolumab with ALT-803 NCT02523469 Recruiting
Alectinib and bevacizumab NCT02521051 Recruiting
VX-970 and topotecan hydrochloride NCT02487095 Recruiting
Entinostat+pembrolizumab NCT02437136 Recruiting
Genetically modified t-cells NCT02408016 Active, not recruiting
PDR001 NCT02404441 Recruiting
PBF-509_80 mg, PBF-509_160 mg, PBF-509_320 mg and PDR-001 NCT02403193 Recruiting
Anti-cd27 (varlilumab) and Anti-pd-1 (nivolumab) NCT02335918 Active, not recruiting
Epacadostat+nivolumab NCT02327078 Recruiting 




Biomarker-targeted second-line therapy NCT02154490 Recruiting 
Phase III Docetaxel+plinabulin versus docetaxel+placebo NCT02504489 Recruiting
Nivolumab after surgery NCT02595944 Recruiting
Atezolizumab+carboplatin or cisplatin+pemetrexed vs carboplatin or 
cisplatin+pemetrexed 
NCT02657434 Recruiting
Clinical observation, crizotinib, laboratory biomarker analysis NCT02201992 Recruiting
Atezolizumab (MPDL3280A) versus platinum agent (cisplatin or 
carboplatin)+(pemetrexed or gemcitabine) 
NCT02409342 Recruiting





Cytology specimen collection procedure, laboratory biomarker analysis NCT02178163 Recruiting
Genetic testing NCT02194738 Recruiting
Nintedanib NCT02299141 Recruiting 
ALK: Anaplastic lymphoma kinase
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Interventions for HER2 mutations
•	 Lapatinib,	tested	in	a	phase	II	trial	as	an	oral	reversible	dual	TKI	of	
EGFR and HER2 [60].
•	 Afatinib,	evaluated	in	a	phase	II	study,	in	which	HER2	mutated	five	
patients with advanced adenocarcinoma treated, 3 out of which were 
evaluable for response. Objective response observed in all three, even 
after the failure of other EGFR- and HER2-targeted treatments [60].
•	 Neratinib,	is	an	irreversible	pan	ErbB-receptor	family	blocker,	has	
been evaluated in a phase I trial in combination with temsirolimus 
by preclinical data suggesting synergy of HER2 inhibition and 
mTOR inhibition in lung cancer models [60]. It has also studied 
in a phase II trial with advanced NSCLC followed by erlotinib or 
gefitinib.	Response	 rates	 in	 subgroups,	 including	EGFR	mutant,	
wild-type EGFR and EGFR TKI naive- adenocarcinoma with a light 
smoking history compared and results found 3.4%, 0% and 0%, 
respectively.	Only	 a	 small	 subgroup	of	 patients	 benefited	 from	
neratinib and based on these results; neratinib is no longer in 
development for NSCLC [61].
•	 Dacomitinib,	is	an	irreversible	pan-HER	TKI,	and	it	tested	in	a	phase	
II	cohort	of	patients	with	HER2-mutant	or	amplified	lung	cancers.	
An overall response rate in the 26 HER2-mutant patients was 13%, 
and	no	 response	 rate	 in	 four	patients	with	HER2	amplification	
or the 2 with HER2 point mutations observed with Dacomitinib 
treatment [60]. Preliminary data of study in the HER2-mutant 
cohort reveal a partial response rate and 27% of the patients have 
maintained stable disease to date [61].
•	 Trastuzumab,	not	exhibited	significant	clinical	activity	 in	a	phase	
II trial performed by the Cancer and Leukemia Group B as a single-
agent against HER2 2+ or 3+ non-small cell lung carcinoma. However, 
randomized phase II trial investigated the addition of trastuzumab 
to gemcitabine and cisplatin, in 103 previously untreated HER2-
positive NSCLC patients. Trastuzumab was given both concomitantly 
with chemotherapy and as maintenance. Although the combination 
well	tolerated,	it	failed	to	show	a	survival	benefit	in	all	HER2	IHC-
positive lung cancer overall. The Eastern Cooperative Oncology 
Group, evaluated the combination of carboplatin, paclitaxel and 
trastuzumab in patients with HER2-positive (1+ to 3+) NSCLC in a 
phase II study and overall survival was found to be like historical 
Table 8: Some clinical trials targeted as ALK in different phases are going in an unknown location mentioned below [48]
Phase Drug candidate Protocol id Current status
Phase I Mogamulizumab+docetaxel NCT02358473 Completed
Ganetespib and ZIV-aflibercept NCT02192541 Terminated
Immune checkpoint inhibitor and 
erlotinib hydrochloride or crizotinib 
NCT01998126 Active, not recruiting
Erlotinib hydrochloride and 
quinacrine dihydrochloride 
NCT01839955 Completed
Phase II Dabrafenib and trametinib NCT01336634 Completed
Targeted enzyme inhibitor therapy NCT01306045 Recruiting
Azacitidine and entinostat before 
chemotherapy 
NCT01935947 Terminated
Lenvatinib (E7080) NCT01877083 Active, not recruiting
Phase III Ceritinib, pemetrexed, docetaxel NCT01828112 Active, not recruiting 
No phase specified Laboratory biomarker analysis NCT00900328 Completed 
Table 9: In USA, clinical trials targeted as ROS1 in different phases are going on mentioned below [53]
Phase Drug candidate Protocol id Current status
Phase I IPI-549, nivolumab NCT02637531 Recruiting
Pembrolizumab and laboratory biomarker analysis NCT02595866 Recruiting
Phase II Entrectinib (RXDX-101) NCT02568267 Recruiting
Pemetrexed disodium NCT02426658 Recruiting
Stereotactic body radiation therapy NCT02314364 Recruiting
Paclitaxel NCT01702844 Active, not recruiting
Cabozantinib-s-malate NCT01639508 Recruiting
Phase I, Phase II PF-06463922, crizotinib NCT01970865 Active, not recruiting
ROS1: ROS proto-oncogene 1
Table 10: Some clinical trials targeted as ROS1 in different phases at unknown locations mentioned below [53]
Phase Drug candidate Protocol id Current 
status
Phase I Erlotinib hydrochloride and quinacrine dihydrochloride NCT01839955 Completed
ROS1: ROS proto-oncogene 1
Fig. 5: Cell signaling of HER2. Growth factor binding to 
EGFR results in activation of the MAPK signaling pathway 
(RAS-RAF-MEK-ERK) and the phosphatidylinositol 3-kinase 
(PI3K) pathway (PI3K-AKT-mTOR). The letter “K” within the 
schema denotes the tyrosine kinase domain.
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data using carboplatin and paclitaxel alone, while patients with 3+ 
HER2 expression did well in contrast to historical data [60].
•	 Pertuzumab,	is	a	humanized	monoclonal	anti-HER2	antibody	which	
is	also	first-in-class	HER2	dimerization	inhibitor,	and	that	prevents	
HER2 dimerization and inhibits HER2 signaling. In a phase II trial, 
chronic NSCLC patients showed no response in 43 patients after 
pertuzumab monotherapy, but information on the mutational status 
of HER2 in these patients is lacking [60].
Clinical trials on HER2
In the USA, 16 clinical trials in Phase II (NCT02482311; NCT02327468; 
NCT02309177; NCT02157792; NCT02482311; NCT02327468; 
NCT02309177); Phase II (NCT02498613); Phase I, II (NCT02321540; 
NCT02178722; NCT02321540; NCT02403271) and some clinical trials 
in Phase I (NCT01862081); Phase II (NCT01306045; NCT02289833); 
Phase III (NCT02134015) at unknown locations are going on HER2 as a 
target mentioned in Tables 11 and 12 [59].
KRAS
RAS genes identified as of three types: (1) KRAS (homologous to 
the oncogene from the Kirsten rat sarcoma virus), (2) homologous 
to the oncogene from the Harvey rat sarcoma virus, and (3) NRAS 
(first isolated from a human neuroblastoma). The different RAS 
genes are highly homologous but functionally distinct; the degree 
of redundancy remains a topic of investigation. RAS proteins, small 
GTPases which cycle between an active guanosine triphosphate 
(GTP)-bound and inactive guanosine diphosphate (GDP)-bound 
forms. RAS proteins are a central downstream regulator of growth 
factor receptor signaling and consequently are critical for cell 
proliferation, differentiation, and cell survival. RAS can activate 
several downstream pathways which include the PI3K-AKT-mTOR 
and the RAS-RAF-MEK-ERK pathway, which involved in cell survival 
and cell proliferation (Fig. 1) [62]. RAS implicated in the pathogenesis 
of several cancers. Activating mutations in the RAS gene activate the 
RAS GTPase, even in the absence of growth factor signaling [62]. 
KRAS mutations are especially not unusual in colon cancer, lung 
cancer, and pancreatic cancer [62].
Interventions for KRAS mutations
Lung adenocarcinomas in addition harbors activating mutations in the 
downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to 
be mutually exclusive. As such, no targeted therapies are available for 
KRAS-mutant non-small-cell lung cancer (NSCLC) even though it is not 
clear that KRAS mutational status is a predictor of efficacy [7,63].
Supporting targeted therapies against KRAS comes from several studies 
such as:
•	 Sorafenib,	used	as	second-line	or	beyond	and	KRAS/BRAF	marker	
group who treated with sorafenib had a disease control rate with 
the stability of illness in patients [64].
•	 Erlotinib	and	Gefitinib,	as	per	study	Pao	et al., patients with mutations 
in	EGFR	and	KRAS	in	NSCLC	screened	to	gefitinib	or	erlotinib.	But,	
the results showed that mutations in KRAS-associated with a lack 
of sensitivity to either drug [65].
•	 Trametinib,	may	also	have	activity	in	NSCLC,	in	a	phase	II	trial,	KRAS	
mutant NSCLC patients randomly assigned to either trametinib 
or docetaxel as second-line therapy. There were no statistically 
significant	differences	between	KRAS	mutant	and	KRAS	wild-type	
regarding progression-free survival (PFS) or overall survival (OS). 
In another phase II trial, patients with advanced NSCLC patients 
analyzed by KRAS status treated with docetaxel plus trametinib 
and response rates of approximately less percentage regardless of 
genotype. In another parallel study, treated cancer patients with 
pemetrexed plus trametinib also showed fewer response rates 
regardless of KRAS status as well [63].
•	 Selumetinib,	 is	 an	 inhibitor	 of	MEK1/MEK2	 and	 downstream	
regulator of KRAS, with preclinical evidence of synergistic activity 
with docetaxel in KRAS-mutant cancers [66].
Table 11: In USA, clinical trials targeted as HER2 in different phases are going on mentioned below [58]
Phase Drug Candidate Protocol id Current status
Phase I AZD1775 NCT02482311 Active, not recruiting
INO-1400 vaccine±INO-9012 NCT02327468 Recruiting
Nivolumab with nab-paclitaxel±gemcitabine NCT02309177 Active, not recruiting
VX-970, M6620, gemcitabine, cisplatin NCT02157792 Active, not recruiting
AZD1775 NCT02482311 Active, not recruiting
INO-1400 vaccine±INO-9012 NCT02327468 Recruiting
Nivolumab with nab-paclitaxel±gemcitabine NCT02309177 Active, not recruiting
Phase II Cediranib±olaparib NCT02498613 Recruiting
Phase I, Phase II Ibrutinib NCT02321540 Active, not recruiting
Pembrolizumab (MK-3475)+epacadostat (INCB024360) NCT02178722 Recruiting
Ibrutinib NCT02321540 Active, not recruiting
Ibrutinib+MEDI-4736 NCT02403271 Completed
Table 12: Some clinical trials targeted as HER2 in different phases at unknown locations are going on mentioned below [58]
Phase Drug candidate Protocol id Current status
Phase I GDC-0032+docetaxel or paclitaxel NCT01862081 Completed
Phase II Targeted enzyme inhibitor therapy NCT01306045 Recruiting
Trastuzumab emtansine NCT02289833 Active, not recruiting
Phase III Patritumab±erlotinib NCT02134015 Terminated 
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Clinical trials on KRAS
In the USA, nine clinical trials in Phase I (NCT02071862; 
NCT01912625; NCT01911507; NCT01859026); Phase II 
(NCT02047344; NCT01829217; NCT01752400; NCT02642042); 
Phase III (NCT02152631) and some clinical trials at unknown locations 
in Phase II (NCT02258607; NCT01988896); Phase II (NCT01877083; 
NCT01306045); no specified Phase (NCT00900328) are going on KRAS 
as a target mentioned in Tables 13 and 14 [62].
MEK1 - (MAP2K1)
MEK1 is the principal mediator of the MAP kinase signaling pathway. It 
is a receptor serine-threonine protein kinase, and it involved in many 
cellular processes, including cell proliferation, differentiation, and 
transcriptional regulation [67].
INTERVENTIONS FOR THE MEK1 MUTATIONS
•	 Selumetinib,	 is	 an	oral,	MEK1/MEK2	kinases	 selective	 inhibitor,	
and using preclinical data of KRAS mutant NSCLC xenograft models, 
indicated	significant	inhibition	of	tumor	growth	by	selumetinib	[68].
•	 Trametinib,	is	also	an	oral,	MEK1/MEK2	kinases	selective	inhibitor,	
and it revealed activity in cell line and xenograft models and RAS 
mutant models [68].
Clinical trials on MEK1
No clinical trials found for the MEK1 target.
NRAS – sub-type RAS gene family
The different types are of RAS genes functionally distinct but highly 
homologous. It is a subtype of RAS family and first isolated from a 
human neuroblastoma. RAS proteins are small GTPases, which cycle 
between active GTP-bound and inactive GDP-bound forms. These 
proteins are central mediators downstream of growth factor receptor 
signaling and therefore are crucial to cell proliferation, differentiation 
and cell survival. RAS downregulate PI3K-AKT-mTOR and RAS-RAF-
MEK-ERK pathway, involved in cell survival and cell proliferation 
(Fig. 1) [69]. NRAS mutations most commonly in melanoma, myeloid 
leukaemias, and thyroid carcinoma, hepatocellular carcinoma [69].
Interventions for the NRAS mutations
•	 Binimetinib,	 showed	robust	activity	 specifically	 in	NRAS-mutant	
melanoma and an allosteric MEK1/2 inhibitor [70].
•	 Selumetinib,	 is	 a	 farnesyltransferase	 inhibitor	 (FTI)	which	 is	 a	
second-generation inhibitor of MEK1/2 and also having potent 
inhibition of both RAS and RAF-mutant cancers. Further clinical 
trials of FTIs in melanoma are not ongoing [70].
•	 Trametinib,	is	an	MEK1/2	allosteric	inhibitor.
•	 Sorafenib	is	an	inhibitor	of	a	multitargeted	kinase	and	tivantinib,	a	
MET inhibitor, also an active against NRAS-mutant melanoma [70].
•	 SCH772984,	was	 efficacious	 in	 cell	 lines	with	NRAS,	KRAS,	 and	
BRAF mutations as well as in models of BRAF inhibitor-resistant 
melanoma [70].
•	 Heat	 shock	protein-90,	may	have	 a	 role	 in	 the	 single	 agent,	 or	
combination therapy showed promising activity in NRAS-mutant 
melanoma inhibition [70].
•	 Immune-based	 therapies,	 such	 as	 high-dose	 interleukin-2,	
ipilimumab is a monoclonal antibody to cytotoxic T lymphocyte 
antigen-4 (CTLA4), agents targeting programmed cell death-1 
receptor and its ligand (PD-1/PDL-1) Nivolumab (BMS-936558) and 
pembrolizumab (MK-3475) are some other options for the treatment 
in NRAS mutations [70].
Clinical trials on NRAS
Some clinical trials in Phase II (NCT01306045) at unknown locations 
are going on NRAS as a target is mentioned in Table 15 [69].
PIK3CA
PI3K are a family of lipid kinases concerned in a lot of cellular processes, 
along with cell growth, differentiation, proliferation, motility, and 
survival. PI3K is a heterodimer composed of 2 subunits110 kDa 
Table 13: In USA, clinical trials targeted as KRAS in different phases mentioned below [61]
Phase Drug candidate Protocol id Current status
Phase I Glutaminase inhibitor CB-839 and Pac-CB NCT02071862 Recruiting
Trametinib, combination chemotherapy, and radiation therapy NCT01912625 Recruiting
INC280 and erlotinib hydrochloride NCT01911507 Recruiting
MEK162 and erlotinib hydrochloride NCT01859026 Recruiting
Phase II Antroquinonol NCT02047344 Recruiting
Sunitinib malate NCT01829217 Active, not recruiting
AUY922 NCT01752400 Active, not recruiting
Trametinib and docetaxel NCT02642042 Recruiting
Phase III Abemaciclib (LY2835219) NCT02152631 Active, not recruiting
Table 14: Some clinical trials targeted as KRAS in different phases at unknown locations mentioned as follows [61]
Phase Drug candidate Protocol id Current status 
Phase I Momelotinib+trametinib NCT02258607 Terminated
Atezolizumab+cobimetinib NCT01988896 Active, not recruiting
Phase II Lenvatinib (E7080) NCT01877083 Active, not recruiting 
Targeted enzyme inhibitor NCT01306045 Recruiting
No phase specified Laboratory biomarker analysis NCT00900328 Completed 
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catalytic subunit and 85 kDa regulatory subunit (p85). The PIK3CA 
gene	 also	 encodes	 p110α,	 one	 of	 the	 catalytic	 subunits	 [71].	 PI3K	
converted PI (4,5) P2 (Phosphatidylinositol 4,5-bisphosphate) to PI 
(3,4,5) P3 (Phosphatidylinositol [3,4,5]-trisphosphate) on the inner 
side of the cell membrane. PI (3,4,5) P3 recruits crucial downstream 
signaling proteins, inclusive AKT, to the cell membrane resulting in 
increased activity of these proteins [71]. PIK3CA mutation implicated in 
the pathogenesis of numerous cancers, including colon cancer, gliomas, 
breast cancer, gastric cancer, endometrial cancer, and lung cancer [71].
Interventions for the PIK3CA mutations
Currently, several inhibitors directed against PI3K are being clinically 
evaluated for NSCLC treatment as follows:
•	 PX-866,	is	a	pan	class-I	PI3K	inhibitor	that	binds	PI3K	irreversibly	
and developed from biologically stable semisynthetic viridins [72].
•	 NVP-BKM120,	GDC-0941,	 XL147,	 are	 specific	 pan-class	 I	 PI3K	
inhibitors [72].
•	 BAY	80-6946,	represents	a	novel,	highly	selective	and	potent	pan-




next-generation PI3K inhibitor [72].
Clinical trials on PIK3CA
In the USA, eight clinical trials in Phase 0 (NCT02357836); Phase 
I (NCT02079636; NCT01920061; NCT01859026); Phase II 
(NCT02642042; NCT01827384) and some clinical trials in Phase I, II 
(NCT02393209) at unknown locations are going on PIK3CA as a target 
mentioned in Tables 16 and 17 [71].
RET
The RET gene belongs to the RET family of RTKs and positioned on 
chromosome 10 and encodes a RTK. This gene plays a significant 
role in neural crest development. Binding of its ligands, the glial cell 
line-derived neurotrophic factor family of extracellular signaling 
molecules, regulates receptor phosphorylation and activation. After 
phosphorylation RET-activated, then its substrates, resulting in 
activation of multiple downstream cellular pathways (Fig. 6) [73]. 
Genomic alterations in RET found in several different types of cancer. 
Activating point mutations in RET can give rise to the hereditary cancer 
syndrome, multiple endocrine neoplasias 2 (MEN2). Somatic point 
mutations in RET also associated with sporadic medullary thyroid 
cancer. Oncogenic kinase fusions involving the RET gene found in ~1% 
of NSCLC [73].
Interventions for the RET mutations
•	 Sorafenib,	 has	potent	 anti-RET	activity	 and	also	 a	multi-kinase	
inhibitor. Since, sorafenib did not show dramatic results, the study 
suggesting for testing of other RET inhibitors in the treatment of 
RET fusion-positive NSCLC [74].
•	 Sunitinib,	is	a	RET	tyrosine	kinase	inhibitor,	and	preclinical	data	of	
sunitinib suggest that it can play an important role in the clinical 
development of NSCLC treatment [74,75].
•	 Cabozantinib,	 in	 patients	 with	 RET	 fusion-positive	 NSCLC	
cancer, provides new drug treatment paradigm in lung cancers. 
Toxicities related to cabozantinib are manageable and RET fusion 
investigations [76].
•	 Vandetanib,	is	a	RET	inhibitor	in	NSCLC	patients	[77].
In unselected NSCLC patient, clinical trial conducted, but all these drugs 
did not show a survival benefit in RET mutations in NSCLC.
Clinical trials on RET
In the USA, eight clinical trials in Phase I (NCT02608385; 
NCT02409108); Phase II (NCT02544633; NCT02498613; 
NCT02426658; NCT02312622; NCT02132598; NCT02045446; 
NCT01935336; NCT01928576;
NCT01829217; NCT01822496; NCT01813734; NCT01702844; 
NCT01639508); Phase III (NCT02595944); no specified Phase 
(NCT02299141; NCT02194738; NCT02193152) and some clinical trials 
in Phase I (NCT01839955); Phase II (NCT02485652; NCT01877083; 
NCT01306045); Phase III (NCT02296125); Phase IV (NCT02151149) 
at unknown locations are going on RET as a target mentioned in 
Tables 18 and 19 [73].
Table 15: Some clinical trials targeted as NRAS in different phases at unknown locations mentioned as follows [68]
Phase Drug candidate Protocol id Current 
status
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MET
The MET gene (MNNG-HOS transforming gene) present on chromosome 
7 and encodes a RTK which is belonging to the MET/RON family of 
RTKs. After, binding of its ligand called as hepatocyte growth factor 
(HGF; also known as scatter factor), which induces a conformational 
change within the MET receptor that allows receptor phosphorylation 
as well as activation. After phosphorylation of its substrates, resulting 
in activation of multiple downstream pathways within the cell after 
MET activation, including the PI3K-AKT-mTOR pathway, which is 
involved in cell survival, and the RAS-RAF-MEK-ERK pathway, which 
is involved in cell proliferation (Fig. 7). In the context of malignancy, 
aberrant signaling through the MET receptor promotes pleiotropic 
effects, including growth, survival, invasion, migration, angiogenesis, 
and metastasis [78].
The MET receptor and its ligand HGF were mentioned to be aberrantly 
activated in many human cancers. Germline mutations in MET tyrosine 
kinase domain, arise in all of the hereditary papillary renal cell 
carcinomas, Somatic mutations in MET found in 10–15% of sporadic 
papillary renal cell carcinoma. Mutations in MET reported at low 
frequencies in head and neck squamous cell carcinoma, childhood 
hepatocellular carcinoma, NSCLC, and SCLC. Amplification of MET 
reported in gastric cancer, esophageal cancer, colorectal cancer, gliomas, 
clear cell ovarian cancer, and NSCLC [78].
Interventions for the MET mutations
•	 Tivantinib,	 is	dual	EGFR	and	MET	 inhibitors,	with	erlotinib	and	
tivantinib, respectively, tested in non-squamous NSCLC within the 
awful lot anticipated global phase III trial MARQUEE, after Phase II 
data [17].
Table 17: Some clinical trials targeted as PIK3CA in different phases at unknown places as mentioned below [70]
Phase Drug candidate Protocol id Current status
Phase I, Phase II Docetaxel±MLN1117 NCT02393209 Terminated
Table 18: In USA, clinical trials targeted as RET in different phases mentioned below [78]
Phase Drug candidate Protocol id Current status
Phase I Pembrolizumab and stereotactic body radiation therapy NCT02608385 Recruiting
Exatherm total-body hyperthermia NCT02409108 Recruiting
Phase II MGCD265 NCT02544633 Recruiting
Cediranib±Olaparib NCT02498613 Recruiting
Pemetrexed disodium NCT02426658 Recruiting
Pegylated irinotecan NKTR-102 NCT02312622 Recruiting
Cabozantinib-s-malate NCT02132598 Recruiting
Maintenance chemotherapy±stereotactic body radiation 
therapy 
NCT02045446 Active, not recruiting 
Ponatinib hydrochloride NCT01935336 Recruiting
Azacitidine, entinostat, and nivolumab or nivolumab NCT01928576 Recruiting 
Sunitinib malate NCT01829217 Active, not recruiting 
Erlotinib hydrochloride or crizotinib and chemoradiation 
therapy
NCT01822496 Active, not recruiting
Ponatinib hydrochloride NCT01813734 Active, not recruiting 
Paclitaxel albumin-stabilized nanoparticle formulation NCT01702844 Active, not recruiting 
Cabozantinib-s-malate NCT01639508 Recruiting
Phase III Nivolumab after surgery+chemotherapy NCT02595944 Recruiting
No phase specified Nintedanib NCT02299141 Recruiting 
Genetic testing NCT02194738 Recruiting
Pazopanib hydrochloride NCT02193152 Recruiting
RET: Rearranged during transfection
Fig. 6: Signaling pathway rearranged during transfection 
(RET). RET activation involves binding of glial cell line derived 
neurotrophic factor-family ligands as well as interaction with 
GFR alpha receptors, resulting in activation of intracellular MAPK 
and PI3K pathways. The letter “K” within the schema denotes the 
tyrosine kinase domain.
Table 16: In USA, clinical trials targeted as PIK3CA in different phases mentioned below [70]
Phase Drug candidate Protocol id Current status
Phase 0 Itraconazole NCT02357836 Recruiting
Phase I Abemaciclib (LY2835219) NCT02079636 Recruiting
PF-05212384+docetaxel, cisplatin, dacomitinib NCT01920061 Recruiting
MEK-162 and erlotinib hydrochloride NCT01859026 Recruiting
Phase II Trametinib and docetaxel NCT02642042 Recruiting
Molecular profiling-based targeted therapy NCT01827384 Suspended 
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•	 Onartuzumab,	 is	 a	monoclonal	 antibody	 against	MET	 showed	
treatment in a Phase II trial [17].
Clinical trials on MET
In the USA, eight clinical trials in Phase I (NCT01911507); Phase 
II (NCT02544633; NCT02186847; NCT02132598; NCT01639508; 
NCT01588821; NCT01553942); Phase II, III (NCT02154490) and 
some clinical trials Phase II (NCT01928160); no specified Phase 
(NCT00900328) at unknown locations are going on MET as a target 
mentioned in Tables 20 and Table 21 [78].
CONCLUSION
The aim of this review is to analyze the current trends in the targets due 
to the genetic modulation with in the current updates of interventions 
and clinical trials. The treatment of genetic modulated NSCLC and 
the current scenario of drug discovery have been touched in a 
comprehensive way. In future, it will be an important discussion point 
among the all drug scientist. It is also evident that the intervention 
of NSCLC just in regard to the changes in genes or genetic mutations 
that is varied and continues to be studied and analyzed to most benefit 
treatment of NSCLC patients and society as a whole.
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Table 19: Clinical trials targeted as RET in different phases at unknown locations mentioned below [78]
Phase Drug candidate Protocol id Current status
Phase I Erlotinib hydrochloride and quinacrine dihydrochloride NCT01839955 Completed
Phase II HM61713 (BI-1482694) NCT02485652 Active, not recruiting
Lenvatinib (E7080) NCT01877083 Active, not recruiting
Targeted enzyme inhibitor therapy NCT01306045 Recruiting
Phase III AZD9291 vs gefitinib or erlotinib NCT02296125 Active, not recruiting
Phase IV Abraxane+carboplatin NCT02151149 Completed 
RET: Rearranged during transfection
Table 20: In USA, clinical trials targeted as MET in different phases mentioned below [77]
Phase Drug candidate Protocol id Current status
Phase I INC280+erlotinib hydrochloride NCT01911507 Recruiting
Phase II MGCD265 NCT02544633 Recruiting
Chemotherapy and radiation therapy±metformin 
hydrochloride 
NCT02186847 Active, not recruiting
Cabozantinib-s-malate NCT02132598 Recruiting
Cabozantinib-s-malate NCT01639508 Recruiting
Cabozantinib-s-malate NCT01588821 Active, not recruiting
Afatinib dimaleate, combination chemotherapy, and 
radiation therapy 
NCT01553942 Recruiting
Phase II, Phase III Biomarker-targeted second-line therapy NCT02154490 Recruiting
Table 21: Some clinical trials targeted as MET in different phases at unknown locations as mentioned below [77]
Phase Drug candidate Protocol id Current status
Phase II Pemetrexed disodium and carboplatin or cisplatin±erlotinib hydrochloride NCT01928160 Withdrawn 
No phase specified Pilot study of c-MET and p53 expression NCT00900328 Completed 
Fig. 7: Cell signaling pathway for MET. Growth factor binding to 
MET results in activation of the MAPK signaling pathway (RAS-
RAF-MEK-ERK) and the phosphatidylinositol 3-kinase (PI3K) 
pathway (PI3K-AKT-mTOR). The letter “K” within the schema 
denotes the tyrosine kinase domain.
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